Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study
Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection are among the leading causes of chronic liver diseases worldwide. Through the same transmission routes, HBV/HCV coinfection is widespread and aggravates liver damage. In this study, we aimed to assess the safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) and the pre-treatment of tenofovir alafenamide fumarate (TAF) on HBV reactivation in HBV/HCV coinfected patients.
Authors
- Zhan Zeng (ORCID: https://orcid.org/0000-0001-7342-6916)
- 江应安
- 黄祖雄
- Songsong Xie (ORCID: https://orcid.org/0000-0003-0307-6425)
- Jiawei Geng
- Liting Zhang
- Xiaobo Lu
- Yanyan Yu (ORCID: https://orcid.org/0000-0002-7557-1305)
- Ning Lin
- Yuemin Nan
- Hong You
- Qian Kang
- Xiaoyuan Xu (ORCID: https://orcid.org/0000-0002-1759-4330)
- Liaoyun Zhang
- Minghua Su
- Jia Shang
- Biao Wu
- Dazhi Zhang
- Chengzhen Lu
- Yifan Han
- Hongyu Chen
- Zhili Wen
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2026-05-29
- DOI
- https://doi.org/10.14218/jcth.2026.00168
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00